

STONEWOOD GLOBAL FUND PCC LIMITED

(a protected cell investment company registered with limited liability in Guernsey under registration number 59227) (the "Fund")

**STONEWOOD GLOBAL ADVENTUROUS FUND
(the "Cell")**

APPENDIX

The Manager and the Directors of the Fund accept responsibility for the accuracy of the information in this Appendix. To the best of the knowledge and belief of the Manager and the Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this Appendix is in accordance with the facts and does not omit anything likely to affect the import of such information.

The Cell is a cell of Stonewood Global Fund PCC Limited. The Directors resolved to create this Cell on 15 May 2019.

This is an appendix to the scheme particulars of Stonewood Global Fund PCC Limited dated 15 December 2020 as may be amended from time to time (the "**Particulars**").

This Appendix must be read in conjunction with the Particulars and applications for Participating Shares will be accepted only on that basis.

Words defined in the Particulars unless otherwise defined shall have the same meaning in this Appendix.

Dated 15 December 2020

INTRODUCTION

The Cell

The Cell is a cell of the Fund, which is an open-ended collective investment scheme, constituted as a protected cell company under the Companies Law registered with limited liability in Guernsey on 28 October 2014.

The Participating Shares

Participating Shares in the Cell will be issued in three Classes: Class A, Class B and Class T. Each Class may have a different minimum initial subscription level or a different Management Fee charged in respect of it but will otherwise be issued on the same terms and have the same rights attributed to them - see the sections below headed "Fees and Expenses" and "Terms and Conditions of the Cell Participating Shares".

Class A shares are available to new investors, however Class B shares are only available to existing internal clients of the Fund. Investments in the Class T shares are restricted to a limited investor base.

INVESTMENT PARTICULARS

Investment Objectives

The Cell targets a return of US CPI + 4% per annum. The Cell seeks to balance appreciation of capital and risk of loss to provide capital growth over the long term with a global diversified portfolio of equities, fixed income securities, listed real estate, alternative asset and commodity linked instruments.

The Cell uses the Morningstar® US Moderate Target Allocation Index as its benchmark. This index family is designed to give investors an unbiased tool to benchmark the performance of the Cell against peers in the same risk category classification. The Morningstar Category Classifications for asset allocation funds are well accepted by the investment management industry and provide investors a consistent peer group to benchmark the Cells' performance against. The benchmark is made up of a host of indexes that match the aggregate asset allocation of the Morningstar Category peer group with rebalancing taking place monthly and asset weights being adjusted annually. The Cell seeks to achieve income and/or capital returns through a fully flexible portfolio comprising approximately 20% to 90% in global equities and the balance in bonds and other securities.

Investment Strategy

The Cell is an Active Asset Allocation Fund seeking to generate a targeted level of return over the long term through a considered asset allocation strategy by investing in a portfolio of Exchange Traded Funds, low cost Index Funds and selected Active Fund Managers that enable the targeted asset allocation to be achieved at relatively low cost.

The Cell will always have equity exposure of between 20% and 90% of its net asset value. Within this range the asset allocation decision will be driven by the Manager's view of value within different asset classes, geographies, and sectors.

The Cell will primarily invest in securities that are denominated in US\$ but will also invest in securities denominated in currencies other than the share class currency. Movements in currency exchange rates can affect the return of investments.

Income from the Cell will be reinvested and reflected in the net asset value of the Participating Shares.

The investment strategy may be varied at the discretion of the Directors (following consultation with the Manager) if, in their opinion, a different investment strategy might better achieve the investment objectives of the Cell. Investors in the Cell will be given prior notice of any such variation and the Directors will allow at least one redemption cycle to complete before implementing such variation.

Risk Considerations

There are a number of factors that impact the Cell's risk exposure and probability of losses. The values of equities and bonds can be affected by factors such as stock market movements, interest rates, credit spreads, and volatility. Other driving factors include political, economic news, company earnings, and significant corporate events. Foreign currency movements can also affect the return of investments. The Cell will have certain exposure to emerging markets, these markets generally are more sensitive to economic and political conditions, as well as certain liquidity risks.

Investment Restrictions

The following investment restrictions shall apply to the Cell:

- (a) No more than 10% of the Net Asset Value attributable to the Cell may be invested in any particular security. This restriction will not apply to US Treasury Bills with a maturity of less than 12 months.
- (b) No more than 40% of the Net Asset Value attributable to the Cell may be invested in positions of more than 5%. This restriction will not apply to US Treasury Bills with a maturity of less than 12 months.
- (c) No more than 10% of the Net Asset Value attributable to the Cell may be invested in shares that are not traded on an exchange that is a member of, or is owned by a full member of, the World Federation of Exchanges. The New York Stock Exchange and the London Stock Exchange will, for these purposes, always be treated as if they are full members of the World Federation of Exchanges.
- (d) No more than 10% of the Net Asset Value attributable to the Cell may be invested in unlisted securities and such securities must be valued on at least a weekly basis utilising a generally recognised methodology.

- (e) Any Collective Investment Schemes that the Cell may invest in are limited to those that have a risk profile that is not significantly higher than the risk profile of the Cell. The Cell may not invest in a collective investment scheme that can invest more than 10% of its own assets in other collective investment schemes. For the avoidance of doubt, an exchange traded fund is not a Collective Investment Scheme.
- (f) The Cell may not invest in a fund of funds or a feeder fund.
- (g) Derivatives may be used only for efficient portfolio management purposes. The Cell may use derivatives to switch its exposure from one currency to another. Unlisted derivatives may be used only in respect of foreign currency, interest rate and exchange rate swap transactions. The Cell may not transact in uncovered derivatives.
- (h) The Cell may not pledge its assets other than to post collateral in support of permitted derivative transactions.
- (i) The Cell may not invest in other collective investment schemes or exchange traded funds with leveraged exposure to underlying assets.
- (j) Short selling of securities by the Cell is not permitted.
- (k) The Cell will not enter into stock lending or stock borrowing transactions.
- (l) The Cell is not permitted to invest in an instrument that compels the acceptance of physical delivery of a commodity.
- (m) The Cell is not permitted to invest in synthetic financial instruments.

The above restrictions (a), (b), and (e) apply as at the date of the relevant transaction or commitment to invest. Changes in the portfolio do not have to be effected merely because, owing to appreciations or depreciations in value, redemptions or by reason of the receipt of, or subscription for, any rights bonuses or benefits in the nature of capital or of any acquisition or merger or scheme of arrangement for amalgamation, reconstruction, conversion or exchange or of any redemption, any of the restrictions would thereby be breached, but regard shall be had to these restrictions when considering changes or additions to the portfolio.

The investment restrictions may be varied at the discretion of the Directors (following consultation with the Manager) if in their opinion different investment restrictions might better achieve the investment objectives of the Cell. Investors in the Cell will be given prior notice of any such variation and the Directors will allow at least one redemption cycle to complete before implementing such variation.

Borrowing Powers

The Cell may not incur any borrowings other than for the purpose of providing funds to satisfy requests by Shareholders for the redemption of their Participating Shares. Such borrowings must not exceed 10% of the Cell's Net Asset Value at the time of borrowing nor be outstanding for more than 90 days. Hedging transactions shall not constitute borrowings for this purpose.

Ideal Investors

The Cell is suitable for investors who are seeking capital growth as a primary objective but also want to limit the risk of capital loss by holding a fully flexible and diversified global portfolio of equities, fixed income securities, listed real estate and Commodity Linked Instruments. Investors should have a moderate to high risk level, tolerate a medium to high level of volatility in the value of their investment and preferably have an investment time horizon of at least 7 years. Investors should be able to evaluate the risks and strategy of investing in the Cell and to bear the economic consequences of investment in the Cell including the possibility of any loss arising from the investment. Further, the Cell is only suitable for investors who are able to make a minimum investment of US\$100,000.

Prospective Investors should be aware that the investment objective and policies established in relation to Participating Shares in the Cell are subject to the "Risk Factors" outlined in the Particulars and this Appendix.

MANAGEMENT AND ORGANISATION

Investment Adviser

Stonewood Asset Management (Pty) Ltd has been appointed, pursuant to an Investment Advisory Agreement dated 1 August 2020, as Investment Advisor to the Cell.

Prime Brokers

The Fund may appoint one or more Prime Brokers under a Prime Brokerage Agreement to provide prime brokerage services to the Cell. These services will include general dealing, execution, and settlement services. The Fund reserves the right to change the Prime Brokerage arrangements described above by agreement with the Prime Broker and/or, in its discretion, to appoint additional or alternative Prime Broker(s). Where the Cell trades in, inter alia, futures or options, the Fund will appoint a Prime Broker to hold such assets. Any appointment of a Prime Broker is conditional on the GFSC receiving an application for, and granting consent to, a derogation under the Class B Rules. Subject to the terms of such derogation, the Custodian will not be responsible for the custody and control of those assets or the actions of any Prime Broker in respect of those assets. At the date of this Appendix no derogation has been applied for or granted.

FEES AND EXPENSES

Initial Fee:	None.										
Annual Management Fee:	Class A - 0.50% of the NAV of the Cell attributable to the Class A Shares; Class B - 0.00% of the NAV of the Cell attributable to the Class B Shares; Class T - 0.35% of the NAV of the Cell attributable to the Class T Shares;										
Custody Fee:	<p>Brokerage: (no minimum fee)</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 80%;">Equities</td> <td style="text-align: right;">0.20%</td> </tr> <tr> <td>ETF</td> <td style="text-align: right;">0.20%</td> </tr> <tr> <td>Bonds</td> <td style="text-align: right;">0.20%</td> </tr> <tr> <td>Mutual funds</td> <td style="text-align: right;">0.20%</td> </tr> <tr> <td>Futures</td> <td style="text-align: right;">15 CHF per contract</td> </tr> </table> <p>Safekeeping account/Custody: 0.08% p.a.</p> <p>Forex: Spot, Forwards and Swaps: 8 bps</p> <p>Lombard/Fixed Advanced borrowing facility LIBOR + 0.75%</p> <p>NOTE: All fees quoted exclude third-party charges and stock exchange fees.</p>	Equities	0.20%	ETF	0.20%	Bonds	0.20%	Mutual funds	0.20%	Futures	15 CHF per contract
Equities	0.20%										
ETF	0.20%										
Bonds	0.20%										
Mutual funds	0.20%										
Futures	15 CHF per contract										
Administration Fee:	<p>The fees of the Administrator will be paid by the Manager. The fee will be pro-rated across all share classes of the Cell based on their aggregate NAVs:</p> <p>0.15% of NAV on the first US\$100 million; plus 0.10% of NAV between US\$100 – US\$250 million; plus 0.06% thereafter</p> <p>subject to a minimum annual fee of US\$17,500. Shareholder transaction fee: US\$50 per transaction</p> <p>Additional NAV calculation fee: where the Cell requires net asset value calculations more frequently than prescribed in this Appendix, each such additional net asset valuation calculation will incur a further charge of US\$1,000</p> <p>FATCA and CRS fee: FATCA annual service charge is £225 and FATCA and CRS annual reporting charge is £2,500</p>										
Broker Fee (if any):	To be charged at prevailing commercial rates – any such fees will be agreed between the Fund and the Broker and communicated to investors in the Cell separately.										
Investment Adviser Fee:	None - the fees of any Investment Adviser will be paid by the Manager.										

Trail Commissions:	Trail commissions may be paid to named financial advisors, brokers, third party administrators or LIPs up to a maximum of 1.5% per annum of the value of the investor's investment in the Cell and will be charged by way of regular redemption of Participating Shares. Such trail commissions shall be payable quarterly.
---------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TERMS AND CONDITIONS OF THE CELL PARTICIPATING SHARES

Base Currency	US\$
Subscription Price	US\$10.00 per Participating Share initially and thereafter on an Investment Dealing Day at a price calculated in accordance with the Particulars - see the section headed 'Subscriptions'.
Minimum Initial Subscription Amount	Class A - US\$100,000 Class B - US\$100,000 Class T - US\$100,000
Minimum Additional Subscription Amount	Class A - US\$10,000 Class B - US\$10,000 Class T - US\$10,000
Investment Dealing Day	Every Thursday, or if not a Business Day, on the Business Day immediately following.
Redemption Dealing Day	Every Thursday, or if not a Business Day, on the Business Day immediately following.
Subscription Notice Period	Application Forms and cleared funds are to be received by 4pm (Guernsey time) on the Business Day prior to an Investment Dealing Day. If the Application Form or cleared funds are received after the deadline, it will be treated as a request for subscription on the next Investment Dealing Day, unless the Administrator agrees otherwise in any particular case.
Redemption Notice Period	Redemption requests are to be received by 4pm (Guernsey time) on the Business Day prior to a Redemption Dealing Day. If the Redemption Notice is received after the deadline for receipt of requests for redemption for any particular Redemption Day, it will be treated as a request for redemption on the next relevant Redemption Dealing Day, unless the Administrator agrees otherwise in any particular case.
Redemption Proceeds Payment	Payment of the redemption proceeds will be made within 10 Business Days following the applicable Redemption Dealing Day.

Minimum Redemption Amount	US\$10,000
Compulsory Redemption Amount	Below US\$100,000
Conversion Notice Period	Four Business Days prior to each Investment Dealing Day.
Contract Notes	A contract note will be distributed to the applicant on acceptance of the application (for subscription or redemption) within seven Business Days after the relevant Investment Dealing Day or Redemption Dealing Day (as applicable).
Valuation Point	11pm (Guernsey time) on the Business Day immediately preceding an Investment Dealing Day or a Redemption Dealing Day.
Dividends	None.
Exit Penalties	None.
Redemption Fee	None.
Reporting Fund Status	The Fund has applied to HMRC and obtained reporting fund status for Classes A and B of the Cell.